AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present virtually at the BofA Securities  – Tech Solutions for Drug Discovery Conference on Monday, September 20, 2021, at 9:00 a.m. Pacific Time.

A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay will be available through the same link following the presentation.

About AbCellera Biologics Inc.

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development. For more information, please visit


Buy $ABCL on TDAmeritrade

Buy $ABCL on ETrade

Buy $ABCL on Interactive Brokers

Buy $ABCL on  Robinhood

Buy $ABCL on Webull


Last Trade: US$15.53
Daily Change: -0.38 -2.39
Daily Volume: 1,072,578
Market Cap: US$4.330B
AbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021
AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies
Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19
Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19
AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines
AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets
AbCellera Reports Q2 2021 Business Results
EQRx and AbCellera Announce Collaboration to Accelerate the Advancement of New Innovative Medicines
Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-β Superfamily Member for the Treatment of Cancer
AbCellera to Report Second Quarter 2021 Financial Results on August 12, 2021
AbCellera Appoints Neil Berkley as Chief Business Officer
AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada